ArticleHereditas2026
Cancer-associated fibroblasts and immune escape-related genes serve as biological markers for the prognosis of colorectal cancer.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a common malignant tumor with a steadily rising incidence rate, and it is often diagnosed at an advanced stage. Immunotherapy has emerged as a promising alternative to surgical resection. Cancer-associated fibroblasts (CAFs) play a critical role in the tumor microenvironment (TME) and are closely associated with tumor immune evasion. This study aims to identify genes associated with CAFs and immune evasion in CRC, and to explore their underlying mechanisms and potential clinical applications in CRC.
methodsBased on CRC transcriptomic data from TCGA and GEO (GSE39582), this study identified differentially expressed genes associated with tumor-associated fibroblasts and immune evasion (CAFIERDEGs) and performed GO/KEGG functional enrichment analysis on them. A prognostic risk model was constructed based on CAFIERDEGs, followed by survival analysis and validation. Additionally, key genes were identified through the construction of a protein-protein interaction (PPI) network, and differences in immune checkpoint expression, immune cell infiltration, and immunotherapy response were systematically evaluated across different risk groups. Finally, the key genes were experimentally validated using single-cell RNA sequencing, immunohistochemistry, and qPCR.
resultsFive hub genes (SOX2, CXCL11, SPP1, APOE, and CXCL8) were screened. These genes are involved in the regulation of the immune response, cytokine activity, and the Toll-like receptor signaling pathway. CRC patients were classified into two distinct molecular subtypes based on the expression profiles of these genes. The prognostic risk model revealed significant differences in overall survival rates. The tumor immune dysfunction and rejection (TIDE) score was significantly lower in the low-risk group. The tumor mutational burden (TMB) was higher, and the expression of most immune checkpoint genes increased. This indicates a stronger potential reactivity to immunotherapy. Experiments confirmed that the expressions of CXCL8, CXCL11, and SPP1 were significantly upregulated in CAFs, while APOE and SOX2 expressions were significantly downregulated.
conclusionThis study identified five CAFIERGs and constructed a prognostic model for CRC by integrating CAFs and immune escape-related genes. This model can predict the immunotherapy response and prognosis of CRC patients. These findings offer potential therapeutic targets for improving prognostic evaluation and guiding immunotherapy strategies in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.